- freely available
Current and Novel Inhibitors of HIV Protease
AbstractThe design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed.
Share & Cite This Article
Pokorná, J.; Machala, L.; Řezáčová, P.; Konvalinka, J. Current and Novel Inhibitors of HIV Protease. Viruses 2009, 1, 1209-1239.View more citation formats
Pokorná J, Machala L, Řezáčová P, Konvalinka J. Current and Novel Inhibitors of HIV Protease. Viruses. 2009; 1(3):1209-1239.Chicago/Turabian Style
Pokorná, Jana; Machala, Ladislav; Řezáčová, Pavlína; Konvalinka, Jan. 2009. "Current and Novel Inhibitors of HIV Protease." Viruses 1, no. 3: 1209-1239.
Notes: Multiple requests from the same IP address are counted as one view.